Prescription medicine
Scopolamine Brand names: Transderm; first approved as Transderm Scop
Scopolamine (Transderm) is a prescription medicine with an FDA approval on record since 1979. FDA's NDC Directory lists it from 11 generic labelers, and pharmacies paid $4.34 per scopolamine 1 mg/3 day patch in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
Check it at the source: the scopolamine FDA label on DailyMed (effective June 10, 2025, Baxter Healthcare Corporation); the NDA 17874 record on Drugs@FDA; every scopolamine label on DailyMed.
Highlights of the record
FDA label of June 10, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageTRANSDERM SCŌP is indicated in adults for the prevention of:
nausea and vomiting associated with motion sickness.
Forms and strengths
- 1 mg
- 1.5 mg
Extended-release patch; patch; system.
On the market
- Earliest approval on file
- December 31, 1979 Transderm Scop, Baxter Hlthcare Corp; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 7 first January 30, 2015; 7 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 12 of which 11 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $4.34 per patch Scopolamine 1 mg/3 day patch
- Shortage (FDA)
- None current 1 past records
- Recalls by its makers (FDA)
- 2 since 2018 0 Class I among all firms' recalls; latest April 13, 2022
- FAERS reports
- 5,895 through July 30, 2026
What is scopolamine used for?
From the label: indications and usageTRANSDERM SCŌP is indicated in adults for the prevention of:
nausea and vomiting associated with motion sickness.
post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. TRANSDERM SCŌP is an anticholinergic indicated in adults for the prevention of:
nausea and vomiting associated with motion sickness. ( 1 )
post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery.
Conditions named in the indications of scopolamine's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Anticholinergic.
Source: FDA drug label (Transderm Scop), Baxter Healthcare Corporation, effective June 10, 2025 (SPL set b877a694-a1d0-4280-937a-a06820b12a88), via openFDA; the full label on DailyMed
What does the patient leaflet for scopolamine say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while using TRANSDERM SCŌP?You should not drink alcohol while using TRANSDERM SCŌP. It can increase your chances of having serious side effects. • You should not drive, operate heavy machinery, or do other dangerous activities until you know how TRANSDERM SCŌP affects you. • You should not use TRANSDERM SCŌP during a Magnetic Resonance Imaging scan (MRI). Remove TRANSDERM SCŌP before undergoing an MRI. It can cause your skin to burn. • You should be careful if you use TRANSDERM SCŌP while you participate in watersports because you may feel lost or confused (disoriented). • Limit contact with water while swimming and bathing because TRANSDERM SCŌP may fall off. If TRANSDERM SCŌP falls off, throw it away and apply a new one on the hairless area behind your other ear.
From the patient leaflet: How should I store TRANSDERM SCŌP?Store TRANSDERM SCŌP at room temperature between 68°F and 77°F (20°C and 25°C) until you are ready to use it. • Store TRANSDERM SCŌP in an upright position. • Do not bend or roll TRANSDERM SCŌP. Keep TRANSDERM SCŌP and all medicines out of reach of children. The Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration Revised: 06/2025 07-19-00-8984 Figure 1 Figure 2 Figure 3 Figure 4 Figure 5
Source: FDA drug label (Transderm Scop), Baxter Healthcare Corporation, effective June 10, 2025 (SPL set b877a694-a1d0-4280-937a-a06820b12a88), via openFDA; the full label on DailyMed
Is there a generic for scopolamine (Transderm)?
The FDA approved the first generic scopolamine on January 30, 2015. 7 generic applications are approved; 7 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists scopolamine from 11 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1979 earliest approval on file
- 2015 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for scopolamine (Transderm)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $4.34 per Scopolamine 1 mg/3 day patch, down 7% from $4.68 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Scopolamine 1 mg/3 day patch (generic)
- Transderm-scop 1 mg/3 day ptch (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Scopolamine 1 mg/3 day patch | Generic | $4.34 per patch | n/a | -7% |
| Transderm-scop 1 mg/3 day ptch | Brand | $11.02 per unit | n/a | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is scopolamine in shortage?
No scopolamine presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 1 record is all marked to be discontinued, the latest updated November 3, 2025. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46) | Padagis US LLC | To Be Discontinued | November 3, 2025 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has scopolamine been recalled?
The FDA's Enforcement Report lists 2 recalls naming scopolamine since 2018: 0 Class I (the most serious), 2 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| April 13, 2022 | Class II | Mckesson Medical-Surgical Inc. Corporate Office | cGMP deviations: Temperature abuse |
| May 11, 2018 | Class II | L. Perrigo Company | Defective delivery system |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the scopolamine label say about other medicines?
The scopolamine label names 1 other medicine in its interaction, contraindication or warning sections. The labels of 3 other medicines name scopolamine. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Meclizine | drug interactions | … and alcohol) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may potentiate the effects of TRANSDERM SCŌP [see Warnings and Precautions ( 5.2 )]. |
Other labels that name scopolamine
Source: FDA drug label (Transderm Scop), Baxter Healthcare Corporation, effective June 10, 2025 (SPL set b877a694-a1d0-4280-937a-a06820b12a88), via openFDA; the full label on DailyMed
What do FAERS reports show for scopolamine?
The FDA Adverse Event Reporting System holds 5,895 reports that list scopolamine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 753 are coded as a death and 1,924 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as scopolamine?
1 other medicine is given the same way (transdermal) and in the same FDA class as scopolamine or labeled mainly for the same use (nausea and vomiting), the same class first. Nausea and vomiting lists all 16 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (transdermal) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Granisetron | Nausea and vomiting | none listed | $685.85 per patch 3.1 mg/24 hr patch | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Other anticholinergics
- the pharmacologic class, with prices and generics
- Scopolamine side effects
- the label's list beside FAERS reports
- Scopolamine shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other